(Q39453882)

12 September 2017

1 reference

title

The neuroleptic malignant syndrome: agent and host interaction (English)

1 reference

neuroleptic malignant syndrome

12 September 2017

main subject

1 reference

Shalev A

1

1 reference

12 September 2017

Munitz H

series ordinal

2

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 April 1986

1 reference

Acta Psychiatrica Scandinavica

12 September 2017

published in

1 reference

12 September 2017

volume

73

1 reference

12 September 2017

issue

4

1 reference

12 September 2017

page(s)

337-347

1 reference

The neuroleptic malignant syndrome

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

Hypertonia and malignant hyperthermia due to morphine and neuroleptic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

Neuroleptic Malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

Neuroleptic malignant syndrome and malignant hyperthermia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

Acute myoglobinuric renal failure. A consequence of the neuroleptic malignant syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

Neuroleptic malignant syndrome complicated by disseminated intravascular coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

Neuroleptic malignant syndrome and dopaminergic blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

Neuroleptic malignant syndrome: response to dantrolene sodium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

Fever, tachycardia, and hypertension with acute catatonic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

Catatonic-like syndrome during neuroleptic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

A paradoxical response to chlorpromazine--a possible variant of the neuroleptic malignant syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

Fatal hyperpyrexia after withdrawal of levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

Comparative Doses and Costs of Antipsychotic Medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1986.TB02694.X

10.1111/J.1600-0447.1986.TB02694.X

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference